May the development of type 2 diabetes mellitus be prevented: Results of the Stop-NDDM sudy
https://doi.org/10.18705/1607-419X-2003-9-3-88-91
Abstract
There are about 150 million patients with diabetes mellitus (DM) in the world and their number will double by 2025. The occurrence of a complete clinical picture of type DM follows a period of glucose intolerance (GI). Enhancing insulin sensitivity and thus affecting GI may prevent the development of type 2 DM and reduce a risk of cardiovascular events. Acarbose (glucobay) is one of the drugs that affect insulin resistance. In the Stop-NDDM study enrolled patients with NI and obesity treated with acarbose for 3 years, the relative risk of type 2 DM decreased by 25% as compared with that in the placebo group. Active therapy caused a reduction in the relative risk of myocardial infarction by 91%, myocardial revascularization procedures by 39%, cerebrovascular disorders and stroke by 44%, and cardiovascular death by 45%.
About the Author
I. Ye. Chazova
НИИ кардиологии им. А.Л.Мясникова РК НПК Минздрава РФ
Russian Federation
Russian Federation
References
1. King H, Aubert RE,Hertnan WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projection. Diabetes Care 1998; 21:1414-31.
2. Tripatby D, Carisson M, AImegren P et al. Insulin secretion and insulin sensivity in relation to glucose tolerance: lessons from the Botnia study. Diabetes 2000; 49: 975-80.
3. Diabetes Mellitus: Report of a WHO Study Group. World Health Organ Tech Rep Ser 1985; 727:1-113.
4. Perry C, Shankar R, Fineberg N et al. IIb Al с measurement improves the detection of type 2 diabetes in high - risk individuals with nondiagnostic levels of Jastinf plasma glucose. Diabetes Care 2001; 24:465-71
5. Tanaka Y, Atsumi Y, Asahina T et al. UseJiilness of revised fasting plasma glucose criterion and characteristics of the insulin response to an oral glucose load in newly diagnosed Japanese diabetic subjects. Diabetes Care 1998; 21:1133-7.
6. Ko G, Chan JJeung V et al. Combined use of a fasting plasma glucose concentration and Hb A Ic or fructosamine predicts the likelihood of having diabetes in high - risk subjects. Diabetes Care 1998; 21:1221 -5.
7. Barrett-Connor E, FerraraA Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men: the Rancho Bernardo study. Diabetes Care 1998; 21:1236-9
8. Mannucci E, Bardini G, Ognibene A et al. Screeningfor diabetes in obese patients using the new diagnostic criteria. Diabetes Care 1998; 21:468.
9. DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American DiabetesAssociation diagnostic criteria. Lancet 1999; 354: 617-21.
10. Tominaga M, Eguchi H, Manaka H et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22:920—4.
11. Wenying J, Lixiang L, ZhiqingI et al. The preventative effect of acarbose and metformin on the progression to diabetes mellitus inthe IG Tpopulation: a 3-year multicentre prospective study.ChinJ Endicrinol Metab 2001; 17: ІЗІ-6.
12. Chiasson JL, Josse R, Gomis R et al. Acarbose for prevention of type 2 diabetes mellitus for prevention of type 2 diabetes mellitus: the Stop - NDDM randomised trial.Lancet 2002; 359'· 2072-7
Review
For citations:
Chazova I.Ye. May the development of type 2 diabetes mellitus be prevented: Results of the Stop-NDDM sudy. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2003;9(3):88-91. (In Russ.) https://doi.org/10.18705/1607-419X-2003-9-3-88-91
Views:
785
Email this article 